Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.

Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.

Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.

Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.

Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.

Abstract: The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.

Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.

Abstract: The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.

Abstract: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.

Abstract: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.

Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract: The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.